A Phase 4 interventional study of zileuton in Asthma, sponsored by Gelb, Arthur F., M.D.. Completed at 1 site in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2007-12-20.
Sponsored by Gelb, Arthur F., M.D. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,696 studies in Asthma with a site in United States — 135 open to participants now, 189 under way, 19 of them phase 3. Asthma · United States.
Among the 1,696 studies in Asthma with a site in United States, this one is the 1,159th largest by enrollment of the 1,354 interventional ones that give a count, is one of 55 that started in 2005, is one of 158 in phase 4, and was the 298th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →135 of the 1,696 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:
University of California, Berkeley · Sites in United States
Ages 13+
Janssen Research & Development, LLC · Sites in United States, Argentina, China and 2 more countries
Ages 18–85
Pfizer · Sites in United States, Puerto Rico
Ages 12–80
GlaxoSmithKline · Sites in United States, Argentina, Canada and 1 more country
Ages 18+
Spiro Medical, Inc. · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 21 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,696 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 151 · Phase 2 338 · Phase 3 276 · Phase 4 158
First in 1990; this study’s year is marked. 55 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 100 across the 1,354 interventional studies, 112 across the 330 observational. Of the 1,402 that completed or were terminated, 626 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
643 of 1,696 have an industry lead sponsor. The 10 most frequent:
Gelb, Arthur F., M.D. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Gelb, Arthur F., M.D. has 3 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
84 of the studies in Asthma with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07671001Phase 3GlaxoSmithKlineA Study of Depemokimab in Participants of 6 to 11 Years of Age | 2027-03-01 |
Add all 84 to your calendar (.ics) → With an account.
Among the 1,696 studies in Asthma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluate the additive role of zileuton 600mg qid to clinically stable asthmatics on Advair 250/50 bid. Since asthma is an endogenous inflammatory disease there usually is increased total exhaled, bronchial and alveolar nitric oxide which are markers of eosinophilic driven pathways of inflammation. The addition of zileuton which is a leukotriene synthesis inhibitor by itself or together with inhaled corticosteroids should reduce nitric oxide gas exchange.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Advair 250/50 (baseline) fluticasone/salmeterol 250/50
Drug: zileuton
zileuton (Zyflo) 600mg qid for 2hr and for 30 days
Also known as: zyflo
nitric oxide gas exchange including total exhaled nitric oxide, bronchial and alveolar nitric oxide
Time frame: 2 hr to 1 month
expiratory spirometry and asthma symptom Juniper score
Time frame: 2 hr to 1 month
The record gives a start of Sep 2005 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zileuton
Gelb, Arthur F., M.D.